GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, has initiated large-scale manufacturing of its recombinant hyperimmune drug for COVID-19 ...
US-based biotechnology company GigaGen has developed a new class of drugs, called recombinant hyperimmunes, to potentially treat patients with Covid-19.
Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment.